N460 Stock Overview
A biotech/life sciences company, focuses on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Medicus Pharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.40 |
| 52 Week High | CA$4.04 |
| 52 Week Low | CA$1.14 |
| Beta | 0 |
| 1 Month Change | 9.09% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 56.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| N460 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 4.0% | 0.7% |
| 1Y | n/a | -10.2% | 8.4% |
Return vs Industry: Insufficient data to determine how N460 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how N460 performed against the German Market.
Price Volatility
| N460 volatility | |
|---|---|
| N460 Average Weekly Movement | 89.9% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: N460's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: N460's weekly volatility has increased from 43% to 90% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Raza Bokhari | medicuspharma.com |
Medicus Pharma Ltd., a biotech/life sciences company, focuses on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. It is developing SkinJect with an indication for basal cell carcinoma. The company is headquartered in Toronto, Canada.
Medicus Pharma Ltd. Fundamentals Summary
| N460 fundamental statistics | |
|---|---|
| Market cap | €31.34m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs N460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N460 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did N460 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 09:07 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medicus Pharma Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Jason McCarthy | Maxim Group |
| Steven Ralston | Zacks Small-Cap Research |